A drug approved slows the progression of Alzheimer’s for the first time in two decades


Washington – The US Food and Drug Administration on Monday approved a controversial new drug to treat Alzheimer’s disease for the first time in 20 years.
The drug, approved by the administration, is aducanumab, which attempts to fight the disease in its early stages by targeting beta-amyloid plaques in the brain to slow the progression of the disease.
In a statement, the administration announced that the drug had been granted “urgent approval”, for use in the treatment of Alzheimer’s disease.
The decision comes after experts from the US Health Agency concluded last year that there was insufficient evidence to support the drug’s effectiveness.
“The data included in the company’s application for the drug was extremely complex and left residual doubts regarding the clinical benefits,” the administration said in its statement.
She added that the drug company “Biogene”, which makes the drug, should conduct “post-approval studies to verify the expected clinical benefit.”
She noted that the Food and Drug Administration “has regulatory actions that could lead to the drug being removed from the market.”
The non-profit Alzheimer’s Association praised the US Food and Drug Administration’s decision to grant approval, saying, “We celebrate the historic decision.”


Please enter your comment!
Please enter your name here